Azhar M. Awan, MD, specializes in treating all solid tumors and lymphomas. He is particularly skilled in the treatment of prostate cancer, soft tissue sarcomas and breast cancer. Dr. Awan is an expert in leading edge cancer treatments, including intensity-modulated radiation therapy (IMRT) and 3-D conformal radiation therapy. He also is skilled in the use of unsealed radioactive sources for treating painful bone metastases.
Dr. Awan has been a contributing researcher in several cancer studies, including early trials that formed the basis of the multidisciplinary head and neck cancer program at the University of Chicago Medicine. These studies evaluated the combined use of radiation therapy and chemotherapy against both untreated and previously irradiated head and neck cancers, using a unique every-other-week treatment schedule. Dr. Awan also has contributed to both the Prostate Cancer Prevention Trial and the SELECT study -- an investigation of vitamin E and selenium in the possible prevention of prostate cancer.
Dr. Awan regularly appears on the Castle Connolly Medical Ltd.'s list of "Top Doctors" in Chicago and in America.
Rush-Presbyterian St. Luke’s Medical Center
Chicago, IL
Residency - Therapeutic Radiology
1985
Rush-Presbyterian St. Luke’s Medical Center
Chicago, IL
Chief Resident - Therapeutic Radiology
1985
Henry Ford Hospital
Detroit, MI
Flexible Internship
1982
Loyola University Stricth School of Medicine
Maywood, IL
M.D.
1981
Loyola University Chicago
Chicago, IL
B.S. - Biology
1978
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41.
PMID: 25234438
Production of TH1 and TH2 cell lines and clones.
Fitch FW, Gajewski TF, Hu-Li J. Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:Unit 3.13.
PMID: 2557305
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control.
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22.
PMID: 15299055
Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy.
Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy. Clin Prostate Cancer. 2004 Jun; 3(1):43-8.
PMID: 15279690
Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making.
Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004 Apr; 45(4):571-8.
PMID: 15073252
Evolution of toxicity after conformal radiotherapy for prostate cancer.
Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5(4):296-303.
PMID: 12627215
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71.
PMID: 11745507
Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience.
Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
PMID: 11134195
Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial.
Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. Int J Cancer. 2000 Oct 20; 90(5):302-4.
PMID: 11091355
PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention.
PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5.
PMID: 10510931